期刊
TRENDS IN BIOTECHNOLOGY
卷 35, 期 11, 页码 1062-1073出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2017.07.004
关键词
-
资金
- Wellcome Trust [104978/Z/14/Z]
- Leverhulme Trust [RPG-2016-015]
- LongeCity
- Methuselah Foundation
- Wellcome Trust [104978/Z/14/Z] Funding Source: Wellcome Trust
Age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriad genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big-data methods and direct-to-consumer (DTC) strategies. Challenges and pitfalls of commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging, and hurdles in performing clinical trials for aging. A large number of potential aging-associated interventions and targets exist, but given the long validation times only a small fraction can be explored for clinical applications. If even one company succeeds, however, the impact will be huge.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据